Patent · US Active

Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same

US9845362B2 · kind B2 · utility

21Cited by
7References
16Claims
0Family size

Assignee

Inventor

Key dates

Filing dateJan 8, 2016
Grant dateDec 19, 2017
Priority date
Expiry dateJan 8, 2036

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2319/60
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Provided are isolated nucleic acid molecules encoding chimeric antigen receptors (CARs) that bind to tumor antigens. Also provided are isolated polypeptides and CARs encoded by the isolated nucleic acid molecules, vectors that include the isolated nucleic acid molecules, cells that include the isolated nucleic acid molecules, methods of making the same, and methods for using the same to generate a persisting population of genetically engineered T cells in a subject, expanding a population of genetically engineered T cells in a subject, modulating the amount of cytokine secreted by a T cell, reducing the amount of activation-induced calcium influx into a T cell, providing an anti-tumor immunity to a subject, treating a mammal having a MUC1-associated disease or disorder, stimulating a T cell-mediated immune response to a target cell population or tissue in a subject, and imaging a MUC1-associated tumor.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.